Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Health professional
Special Considerations for the Treatment of Children With Cancer
Source updated: August 7, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.
The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:
A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.
These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.
Information about these tumors may also be found in sources relevant to adults with cancer.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source updated: August 7, 2024. Captured 2026-09-09.
Treatment options for childhood NUT carcinoma include the following:
Chemotherapy.
Surgery.
Radiation therapy.
Treatment of childhood NUT carcinoma includes a multimodal approach with systemic chemotherapy, surgery, and radiation therapy. Cisplatin, taxanes, and alkylating agents have been used with some success. While early response to these agents is common, tumor progression occurs early in the course of the disease.[1]; [2][Level of evidence C1]
In a report from the NUT Midline Carcinoma Registry, 40 patients with primary tumors in the head and neck were evaluable. The 2-year overall survival rate was 30%. The three long-term survivors (with survivals of 35, 72, and 78 months) underwent primary gross-total resection and received adjuvant therapy.[3]; [4][Level of evidence C1]
Because of the presence of the BRD4::NUTM1 gene fusion in NUT carcinomas, there has been increased interest in evaluating BET bromodomain inhibitors for adults and children with this malignancy.[5] Unfortunately, activity for this class of agents has been limited in reported clinical trials:
In a phase I study of the BET inhibitor molibresib, confirmed objective responses were observed in 2 of the 19 patients who were treated with a daily dose of 60 mg or higher.[6]
A subsequent phase II study of molibresib used a daily dose of 75 mg in patients with NUT carcinomas. Only 1 of the 12 patients achieved an objective response, which did not meet the prespecified bar for activity.[7]
In a phase I study of the BET inhibitor birabresib, three of the nine patients achieved responses, but only one response lasted longer than 2 months.[8]
Source updated: August 7, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
The following are examples of national and/or institutional clinical trials that are currently being conducted:
NCT05019716 (Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment [Etoposide and Cisplatin] for Adult and Pediatric Patients [Aged 12–17 Years] With NUT Carcinoma): This phase I/II trial will determine the maximum tolerated dose of the BET bromodomain inhibitor ZEN-3694 added to cisplatin and etoposide to treat patients with NUT carcinoma. This trial will also evaluate the efficacy of this treatment regimen.
NCT05372640 (Testing the Safety and Efficacy of the Combination of Two Anticancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients [Aged 12–17 years] With Metastatic or Unresectable NUT Carcinoma, Breast Cancer, and Other Solid Tumors): This phase I trial will determine the maximum tolerated dose of the BET bromodomain inhibitor ZEN003694 given with abemaciclib to treat patients with metastatic or unresectable NUT carcinoma, breast cancer, or other solid tumors.
Source updated: December 9, 2024. Captured 2026-09-09.
Because childhood NUT carcinoma is so rare, there is no standard treatment. Often, children receive a combination of treatments to try to control the growth and spread of the cancer:
When possible, surgery is done to remove as much of the tumor as possible.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Childhood NUT carcinoma is treated with external radiation therapy. This way of giving radiation uses a machine outside the body to send radiation toward the area of the body with cancer. Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cells or stops them from dividing. Chemotherapy drugs such as cisplatin, taxanes, and alkylating agents may be used. Learn more about Chemotherapy to Treat Cancer.
Even if the cancer responds to treatment, it will eventually continue to grow and spread. Your child's doctor will talk with you about what to expect and possible next steps. If there are no treatments, your child can receive care to control symptoms from cancer so they can be as comfortable as possible. Joining a clinical trial may be an option. Learn more about clinical trials in the next section.
Studies
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT05372640 · RECRUITING · phase1
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic NUT Carcinoma,...